WO2011033084A1 - Schaltbare ferromagnetische nanoteilchen enthaltende substrate - Google Patents
Schaltbare ferromagnetische nanoteilchen enthaltende substrate Download PDFInfo
- Publication number
- WO2011033084A1 WO2011033084A1 PCT/EP2010/063733 EP2010063733W WO2011033084A1 WO 2011033084 A1 WO2011033084 A1 WO 2011033084A1 EP 2010063733 W EP2010063733 W EP 2010063733W WO 2011033084 A1 WO2011033084 A1 WO 2011033084A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ferromagnetic
- nanoparticles
- switchable
- substrate particles
- temperature
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/05—Metallic powder characterised by the size or surface area of the particles
- B22F1/054—Nanosized particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/825—Metallothioneins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C33/00—Making ferrous alloys
- C22C33/02—Making ferrous alloys by powder metallurgy
- C22C33/0207—Using a mixture of prealloyed powders or a master alloy
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/01—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials
- H01F1/012—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials adapted for magnetic entropy change by magnetocaloric effect, e.g. used as magnetic refrigerating material
- H01F1/015—Metals or alloys
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/14—Treatment of metallic powder
- B22F1/142—Thermal or thermo-mechanical treatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F2998/00—Supplementary information concerning processes or compositions relating to powder metallurgy
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F3/00—Manufacture of workpieces or articles from metallic powder characterised by the manner of compacting or sintering; Apparatus specially adapted therefor ; Presses and furnaces
- B22F3/10—Sintering only
- B22F3/1039—Sintering only by reaction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Definitions
- the invention relates to processes for the preparation of organic substrate particles connected to switchable ferromagnetic nanoparticles, to corresponding diagnostic substrate particles and to the use of such nanoparticles for the treatment of hyperthermia.
- ferromagnetic is understood to mean both “ferromagnetic” and “magnetic”.
- Magnetic particles are already widely used today for marking and manipulating biological objects.
- Antibody-coupled magnetic particles are used, for example, for the magnetic diagnosis of diseases.
- a problem in the production of such small particles in the nanometer range is the tendency of the magnetic particles to form lumps or aggregates. This makes it difficult to uniformly attach the antibodies to the magnetic particles, and the particle size undesirably increases sharply.
- Magnetic particles such as Fe 3 0 4 colloids are used, for example, for hyperthermia treatment, especially in cancer therapy.
- Hyperthermia is a type of cancer treatment in which body tissue is subjected to high temperatures of up to 45 ° C. It has been found that high temperatures can damage and kill cancer cells, usually with only minor side effects on normal tissue. By killing cancer cells and destroying cell structure, hyperthermia can be used to shrink tumors. In doing so, it is desirable to use more suitable magnetic particles which can also be heated by radio waves in the human body.
- the object of the present invention is to provide an improved process for the production of switchable ferromagnetic nanoparticles.
- NEN organic substrate particles which are particularly useful as biomarkers, biosensors, hyperthermia drugs or pharmaceutical carrier materials.
- the object is achieved according to the invention by a method for the production of switchable ferromagnetic nanoparticles having an average particle diameter in the range of 10 to 1000 nm associated organic substrate particles, wherein as ferromagnetic nanoparticles such nanoparticles are used, which are not initially ferromagnetic, but are ferromagnetic at temperature decrease , These first non-ferromagnetic nanoparticles in dispersed form are connected to the organic substrate particles and subsequently by lowering the temperature, the nanoparticles associated with the substrate particles are ferromagnetic.
- the object is further achieved by diagnostic substrate particles containing organic substrate particles connected to switchable ferromagnetic nanoparticles having an average particle diameter in the range from 10 to 1000 nm, wherein the substrate particles have a specific binding action for a substance to be analyzed.
- the object is further achieved by the use of switchable ferromagnetic nanoparticles which become ferromagnetic upon lowering the temperature for the manufacture of a medicament for the hyperthermia treatment of the human or animal body.
- the object is further achieved by a medicament for the hyperthermia treatment of the human or animal body, comprising switchable ferromagnetic nanoparticles having an average particle diameter in the range from 10 to 1000 nm, which become ferromagnetic when the temperature is lowered. It has been found according to the invention that switchable ferromagnetic nanoparticles can be used in a suitable manner for the production of biomarkers, biosensors, hyperthermia active substances or pharmaceutical carrier materials.
- Switchable refers to those ferromagnetic nanoparticles which are initially non-ferromagnetic, but which become ferromagnetic when the temperature is lowered After the preparation of the nanoparticles from the starting materials, they are initially not ferromagnetic, but only when they cool down, whereby the nanoparticles are preferably at ambient temperature (22 ° C) initially not ferromagnetic and are ferromagnetic when lowering the temperature to values below room temperature.
- nanoparticles are meant those particles having an average particle diameter in the range from 10 to 1000 nm, preferably from 20 to 500 nm, in particular from 50 to 200 nm
- the average particle diameter is preferably determined by laser light scattering or electron microscopy
- the lower limit of the particle size is limited by the fact that the particles must still be ferromagnetic at ambient temperature or application temperature, which is typically still the case with a minimum particle diameter of 10 nm
- the non-ferromagnetic nanoparticles are usually used to prepare the substrate particles is introduced into a dispersion, for example an aqueous or water-based dispersion, and is bound in the dispersed form to the organic substrate particles.
- Suitable organic substrate particles are any suitable substrate particles which give the desired effect.
- the organic substrate particles must have suitable anchor groups that allow a connection with the ferromagnetic nanoparticles. It may, for example, be possible for the organic substrate particles to be applied as a coating or shell to the ferromagnetic nanoparticles. Other connections are possible and known in the art.
- the organic substrate particles can be selected from a wide range of suitable substrate particles.
- Biomarkers are, for example, antibodies or biological or organo-synthetic substances that later interact with other substances.
- ferromagnetic nanoparticles can be linked to antibodies that in turn bind with antigens to obtain biomarkers or biosensors. Particles coupled to particular antibodies are used, for example, for magnetic diagnostics of diseases. For a quantitative diagnosis, it is important to be able to use the ferromagnetic nanoparticles with the smallest possible variation of the particle size, since ultimately the proportion of ferromagnetic nanoparticles is counted.
- Biomarkers can z. As in environmental analysis, in the analysis of water and blood, z. B. be used on proteins, carbohydrates or hormones.
- Biosensors can serve to detect any biological ingredients, for example, in liquids or gas streams.
- biosensors use biological systems at different levels of integration.
- biological systems may, for.
- the immobilized biological system of the biosensor interacts with the analyte. This leads to physicochemical changes.
- the determination of glucose in blood during and after surgery is made possible by applying the enzyme glucose oxidase.
- biosensors in the analysis of water and wastewater can be subdivided into biosensors for the determination of individual components, biosensors for the determination of toxicity and mutagenicity as well as in biosensors for the determination of biochemical oxygen demand (BOD).
- BOD biochemical oxygen demand
- the bacterial content of bathing water or sewage can be determined by means of a biosensor.
- the penicillin concentration in a bioreactor, in which fungal strains are cultivated, can be determined with a biosensor.
- the biological component of the sensor used in this case represents the enzyme acylase.
- the organic substrate particles may also be pharmaceutical carrier materials which absorb pharmacologically active substances.
- Such organic polymer substrate particles are described, for example, in WO 2008/044963. It may be referenced in particular on page 16, line 18 to page 17, line 1 1 of this document.
- Bioactive compounds that can be bound to the substrate particles are, for example, antigens, antibodies, nucleotides, gelling agents, enzymes, bacteria, yeasts, fungi, viruses, polysaccharides, lipids, proteins, hormones, hydrocarbons and cell material. These can be used as biosensor materials.
- WO 2008/044963 in particular page 17.
- Biosensors are typically used in compositions of sensors for bioanalytical applications in biotechnology. Examples are immunoassays that are widely used in clinical diagnosis for the detection of diseases or physiological conditions. For a description of the biosensors, reference may be made to WO 2008/044963, page 17, line 25 to page 18, line 17.
- the biomarkers and biosensors are used in particular for the quantitative determination or concentration measurement of biological agents.
- the finally obtained organic substrate particles bonded to the ferromagnetic nanoparticles generally have an average particle diameter in the range of preferably 1, 1 to 5 times, more preferably 1, 2 to 2 times the diameter of the magnetocaloric particles.
- the switchable ferromagnetic nanoparticles are preferably not ferromagnetic at temperatures of 22 ° C. or above and become ferromagnetic by cooling to temperatures of less than 22 ° C.
- the switchable ferromagnetic nanoparticles preferably exhibit a virgin effect of the form that the critical temperature of the transition to the ferromagnetic state (critical temperature 1) is lower during the first cooling of the initially non-ferromagnetic nanoparticles than during the subsequent reheating and cooling (critical temperature 2) ).
- the critical temperature 1 is only passed through during the first cooling, while the critical temperature 2 is passed through during the subsequent heating / cooling cycles.
- the critical temperature 1 is below 22 ° C, preferably ⁇ 0 ° C, especially ⁇ -15 ° C, in particular ⁇ -25 ° C and the critical temperature 2 o- over 22 ° C, z.
- the switchable ferromagnetic nanoparticles can be selected from any suitable nanoparticles.
- the switchable ferromagnetic nanoparticles contain Mn and additionally Fe and / or As and preferably have the Fe 2 P structure or Na-Zn-13 structure. Alternatively, they may contain La, Fe and Si.
- P / As and "Si / Ge” means that in each case phosphorus, arsenic or phosphorus and arsenic or silicon, germanium or silicon and germanium can be present.
- compositions are also described in WO 2008/044963.
- the switchable ferromagnetic nanoparticles preferably exhibit magnetocaloric properties.
- the nanoparticles preferably show a hysteresis and. adi Abatic temperature change from 2 to 6 K / Tesla, z. B. about 4 K / Tesla field strength.
- the hysteresis is preferably at least 5 K.
- the ferromagnetic or thermomagnetic materials used according to the invention can be produced in any suitable manner.
- the output elements are first induction-melted in an argon gas atmosphere and then sprayed in the molten state via a nozzle onto a rotating copper roller. This is followed by sintering at 1000 ° C and slow cooling to room temperature.
- the materials obtained by these methods often show a large thermal hysteresis.
- thermal hysteresis For example, in Fe 2 P-type compounds substituted with germanium or silicon, large values for thermal hysteresis are observed in a wide range of 10 K or more.
- Materials used according to the invention preferably exhibit a hysteresis of at least 5 K, more preferably of at least 6.5 K, preferably in a temperature range between body temperature and above 42 ° C.
- step (a) of the method the reaction of the elements and / or alloys contained in the later ferromagnetic or thermomagnetic material takes place in a stoichiometry corresponding to the ferromagnetic or thermomagnetic material, in the solid or liquid phase.
- the reaction in step a) is carried out by co-heating the elements and / or alloys in a closed container or in an extruder, or by solid-phase reaction in a ball mill.
- a solid phase reaction is carried out, which takes place in particular in a ball mill.
- powders of the individual elements or powders of alloys of two or more of the individual elements, which are present in the later ferromagnetic or thermomagnetic material are typically mixed in powder form in suitable proportions by weight. If necessary, grinding of the mixture may additionally be carried out in order to obtain a microcrystalline powder mixture.
- This powder mixture is preferably heated in a ball mill, which leads to a further reduction as well as thorough mixing and to a solid phase reaction in the powder mixture.
- the individual elements are mixed in the selected stoichiometry as a powder and then melted. The common heating in a closed container allows the fixation of volatile elements and the control of the stoichiometry. Especially with the use of phosphorus, this would easily evaporate in an open system.
- the reaction is followed by sintering and / or tempering of the solid, wherein one or more intermediate steps may be provided.
- the solid obtained in step a) can be pressed before it is sintered and / or tempered.
- the pressing is known per se and can be carried out with or without pressing aids. In this case, any suitable shape can be used for pressing. By pressing, it is already possible to produce shaped bodies in the desired three-dimensional structure.
- the pressing may be followed by sintering and / or tempering step c) followed by cooling or quenching step d).
- the preparation of the nanoparticles may be followed by grinding.
- melt spinning processes are known per se and described for example in Rare Metals, Vol. 25, October 2006, pages 544 to 549 as well as in WO 2004/068512.
- the Meltspinning a high processing speed is achieved because the subsequent sintering and annealing can be shortened. Especially on an industrial scale so the production of ferromagnetic or thermomagnetic materials is much more economical.
- the spray drying also leads to a high processing speed, especially since the desired particle size can be easily adjusted.
- the cooling should not be too fast to obtain sufficiently high hysteresis values.
- a spray cooling may be carried out, in which a melt of the composition from step a) is sprayed into a spray tower.
- the spray tower can be additionally cooled, for example.
- cooling rates in the range of 10 3 to 10 5 K / s, in particular about 10 4 K / s are often achieved.
- the spray cooling can be done in an electric field to obtain monodisperse particles.
- the sintering and / or tempering of the solid takes place in stage c), preferably first at a temperature in the range from 500 to 1800 ° C. for sintering and subsequently at a lower temperature for tempering. These values apply in particular to powders.
- the sintering is preferably carried out for a period of 1 to 50 hours, more preferably 2 to 20 hours, especially 5 to 15 hours.
- the annealing is preferably carried out for a time in the range of 10 to 100 hours, particularly preferably 10 to 60 hours, in particular 30 to 50 hours. Depending on the material, the exact time periods can be adapted to the practical requirements.
- the time for sintering or tempering can be greatly shortened, for example, for periods of 5 minutes to 5 hours, preferably 10 minutes to 1 hour. Compared to the usual values of 10 hours for sintering and 50 hours for annealing, this results in an extreme time advantage.
- the sintering / tempering causes the grain boundaries to melt, so that the material continues to densify.
- stage c) By melting and rapid or slow cooling in stage b), the time duration for stage c) can be considerably reduced. This also enables a continuous production of the ferromagnetic or thermomagnetic materials.
- Particularly preferred according to the invention is the process sequence a) solid phase conversion of chemical elements and / or alloys in a stoichiometry corresponding to the ferromagnetic or thermomagnetic material, in a ball mill, b) melt spinning or shaping of the material obtained in step a), c) annealing the Solid from stage b) for a period of 10 seconds or 1 minute to 5 hours, preferably 30 minutes to 2 hours, at a temperature in the range of 430 to 1200 ° C, preferably 800 to 1000 ° C. d) quenching or cooling the tempered solid from step c).
- step c) grinding of the resulting ribbons into a powder can take place.
- the determination of the particle size of the ferromagnetic nanoparticles is preferably carried out by laser light scattering, as described.
- the switchable ferromagnetic nanoparticles which become ferromagnetic when the temperature is lowered, are preferably used according to the invention for the production of a medicament for the hyperthermia treatment of the human or animal body.
- the nanoparticles are preferably magnetocaloric.
- the hyperthermia treatment is used in particular for the treatment of cancer, as already mentioned above.
- the invention also relates to a medicament for the hyperthermia treatment of the human or animal body, comprising the described switchable ferromagnetic nanoparticles, which become ferromagnetic when the temperature is lowered.
- the particles are preferably ferromagnetic in a cooling.
- the nanoparticles should be ferromagnetic in a temperature range of 37 to 42 ° C. At higher temperatures or preferably at a maximum temperature of 42 ° C., they may lose their ferromagnetic behavior according to an embodiment of the invention. This causes the hysteresis to switch off when overheating, so that the substances lose their ferromagnetic character and can easily be eliminated from the body. This thermal shutdown should be done at higher temperatures than the temperatures at which cancer is destroyed.
- the ferromagnetic nanoparticles are ferromagnetic at ambient temperature (22 ° C.) or at the temperature of use.
- the preferred material used is MnFe (P, Si), which shows the unexpected property that it is non-magnetic after preparation at room temperature (22 ° C). Only after it has cooled down a few degrees below a certain critical temperature is it ferromagnetic at room temperature and above.
- the corresponding properties are shown in the accompanying figure in FIG.
- the figure shows the temperature dependence of the magnetization of MnFeP 0 .5oSio. 5 o-
- the curve (1) shows the virgin effect, ie the behavior at the first cooling.
- the curve (2) shows the behavior during the subsequent heating, (3) during the subsequent cooling.
- the hysteresis of the ferromagnetic material which is significantly larger than 5 K, is very clearly visible.
- the non-magnetic property at the beginning can greatly simplify the attachment of the antibodies, making a magnetic biomarker much simpler than heretofore.
- biocompatibility is not important so that it can be combined with any suitable organic substrate particle.
- the particles according to the invention can also be used as NMR contrast agents. In hyperthermia, it may additionally be of use that the material shown in FIG. 1, once heated above T 2 , is no longer ferromagnetic and thus more easily excreted.
- Evacuated quartz ampoules containing pressed samples of MnFePGe were kept at 1100 ° C for 10 hours to sinter the powder. This sintering was followed by annealing at 650 ° C for 60 hours to homogenize. This was followed by slow cooling in the oven to room temperature.
- the XRD patterns show that all samples crystallize in a Fe 2 P-type structure.
- the thermal hysteresis was determined in a magnetic field of 0.5 Tesla.
- the Curie temperature can be adjusted by varying the Mn / Fe ratio and the Ge concentration, as well as the thermal hysteresis value.
- the material MnFePo.soSio.so was prepared as described in Example 1. The T-dependence of the magnetization is shown in FIG.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nanotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mechanical Engineering (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Metallurgy (AREA)
- Epidemiology (AREA)
- Power Engineering (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Composite Materials (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Manufacturing & Machinery (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010800471353A CN102714080A (zh) | 2009-09-21 | 2010-09-17 | 包含可开关铁磁性纳米颗粒的底物 |
AU2010297237A AU2010297237B2 (en) | 2009-09-21 | 2010-09-17 | Substrates comprising switchable ferromagnetic nanoparticles |
BR112012006267A BR112012006267A2 (pt) | 2009-09-21 | 2010-09-17 | processo para produzir partículas de substrato orgânico ligadas a nanopartículas ferromagnéticas comutáveis, partículas de substrato para diagnóstico, uso de nanopartículas ferromagnéticas comutáveis, e, medicamento para o tratamento de hipertermia no corpo humano ou animal |
EP10762617A EP2481061A1 (de) | 2009-09-21 | 2010-09-17 | Schaltbare ferromagnetische nanoteilchen enthaltende substrate |
RU2012115915/15A RU2554496C9 (ru) | 2009-09-21 | 2010-09-17 | Субстраты, содержащие переключаемые ферромагнитные наночастицы |
JP2012529291A JP6037831B2 (ja) | 2009-09-21 | 2010-09-17 | 切換え可能な強磁性ナノ粒子を含む基板 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09170811.5 | 2009-09-21 | ||
EP09170811 | 2009-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011033084A1 true WO2011033084A1 (de) | 2011-03-24 |
Family
ID=43085806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/063733 WO2011033084A1 (de) | 2009-09-21 | 2010-09-17 | Schaltbare ferromagnetische nanoteilchen enthaltende substrate |
Country Status (10)
Country | Link |
---|---|
US (2) | US8632814B2 (de) |
EP (1) | EP2481061A1 (de) |
JP (1) | JP6037831B2 (de) |
KR (1) | KR20120070590A (de) |
CN (1) | CN102714080A (de) |
AU (1) | AU2010297237B2 (de) |
BR (1) | BR112012006267A2 (de) |
RU (1) | RU2554496C9 (de) |
TW (1) | TWI504397B (de) |
WO (1) | WO2011033084A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE112006004066B4 (de) * | 2006-10-13 | 2012-07-05 | Aleksandr Mettalinovich TISHIN | Magnetischer Träger und medizinisches Präparat zur kontrollierbaren Zuführung und Freisetzung von Wirkstoffen, Herstellungsverfahren dafür und Behandlungsverfahren unter Verwendung davon |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9968549B2 (en) * | 2012-03-23 | 2018-05-15 | King Abdullah University Of Science And Technology | Magnetically controlled permeability membranes |
WO2015089579A1 (en) * | 2013-12-20 | 2015-06-25 | Monash University | Magnetic material for heating |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004068512A1 (en) | 2003-01-29 | 2004-08-12 | Stichting Voor De Technische Wetenschappen | A magnetic material with cooling capacity, a method for the manufacturing thereof and use of such material |
EP1897590A1 (de) * | 2005-06-17 | 2008-03-12 | Obschestvo S Ogranichnnoi Otvetsvennostyu "Perspe | Verfahren zur durchführung einer magnettherapie gegen maligne neoplasmen |
WO2008044963A2 (en) | 2006-10-13 | 2008-04-17 | Aleksandr Mettalinovich Tishin | Magnetic carrier and medical preparation for controllable delivery and release of active substances, a method of production and method of treatment using thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL1018668C2 (nl) * | 2001-07-31 | 2003-02-03 | Stichting Tech Wetenschapp | Materiaal geschikt voor magnetische koeling, werkwijze voor het bereiden ervan en toepassing van het materiaal. |
EP1668424A4 (de) * | 2003-09-12 | 2009-11-25 | Onkor Pharmaceuticals Inc | Magnetisch abzielbare partikel mit magnetischen komponenten und biokompatiblen polymeren für die ortsspezifische ablieferung biologisch aktiver wirkstoffe |
JP4399771B2 (ja) * | 2003-10-08 | 2010-01-20 | 日立金属株式会社 | 磁性粒子とその製造方法、及び磁性粒子ユニット |
US7842281B2 (en) * | 2004-05-10 | 2010-11-30 | The Florida State University Research Foundation | Magnetic particle composition for therapeutic hyperthermia |
JP4624222B2 (ja) * | 2005-09-13 | 2011-02-02 | 戸田工業株式会社 | 導電部形成用粒子 |
WO2007064175A1 (en) * | 2005-12-02 | 2007-06-07 | Industry-Academic Cooperation Foundation, Yonsei University | Magnetic resonance imaging contrast agents containing water-soluble nanoparticles of manganese oxide or manganese metal oxide |
JP2007291437A (ja) * | 2006-04-24 | 2007-11-08 | Hitachi Metals Ltd | 磁気冷凍作業ベッド用の焼結体およびその製造方法 |
CA2694536A1 (en) * | 2007-07-26 | 2009-01-29 | Tokyo Institute Of Technology | Process for production of surface-coated inorganic particles |
-
2010
- 2010-09-17 KR KR1020127010341A patent/KR20120070590A/ko not_active Application Discontinuation
- 2010-09-17 RU RU2012115915/15A patent/RU2554496C9/ru not_active IP Right Cessation
- 2010-09-17 BR BR112012006267A patent/BR112012006267A2/pt not_active IP Right Cessation
- 2010-09-17 WO PCT/EP2010/063733 patent/WO2011033084A1/de active Application Filing
- 2010-09-17 EP EP10762617A patent/EP2481061A1/de not_active Withdrawn
- 2010-09-17 AU AU2010297237A patent/AU2010297237B2/en not_active Ceased
- 2010-09-17 JP JP2012529291A patent/JP6037831B2/ja not_active Expired - Fee Related
- 2010-09-17 CN CN2010800471353A patent/CN102714080A/zh active Pending
- 2010-09-21 US US12/887,138 patent/US8632814B2/en not_active Expired - Fee Related
- 2010-09-21 TW TW099132057A patent/TWI504397B/zh not_active IP Right Cessation
-
2013
- 2013-12-06 US US14/099,176 patent/US20140093934A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004068512A1 (en) | 2003-01-29 | 2004-08-12 | Stichting Voor De Technische Wetenschappen | A magnetic material with cooling capacity, a method for the manufacturing thereof and use of such material |
EP1897590A1 (de) * | 2005-06-17 | 2008-03-12 | Obschestvo S Ogranichnnoi Otvetsvennostyu "Perspe | Verfahren zur durchführung einer magnettherapie gegen maligne neoplasmen |
WO2008044963A2 (en) | 2006-10-13 | 2008-04-17 | Aleksandr Mettalinovich Tishin | Magnetic carrier and medical preparation for controllable delivery and release of active substances, a method of production and method of treatment using thereof |
Non-Patent Citations (4)
Title |
---|
BRUCK E ET AL: "Magnetic-Entropy Change in Mn<tex>$_1.1$</tex>Fe<tex>$_0.9$</tex>P<te x>$_1 - rm x$</tex>Ge<tex>$_rm x$</tex>Compounds", IEEE TRANSACTIONS ON MAGNETICS, vol. 41, no. 10, 1 October 2005 (2005-10-01), IEEE SERVICE CENTER, NEW YORK, NY, US, pages 2778 - 2780, XP011140646, ISSN: 0018-9464, DOI: 10.1109/TMAG.2005.854774 * |
CAM THANH D T ET AL: "Structure, magnetism, and magnetocaloric properties of MnFeP1-xSix compounds", JOURNAL OF APPLIED PHYSICS AIP USA, vol. 103, no. 7, 07B318, 31 January 2008 (2008-01-31), pages 1 - 3, XP002611165, ISSN: 0021-8979 * |
J. APPL. PHYS., vol. 99, 2006, pages 08Q107 |
RARE METALS, vol. 25, October 2006 (2006-10-01), pages 544 - 549 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE112006004066B4 (de) * | 2006-10-13 | 2012-07-05 | Aleksandr Mettalinovich TISHIN | Magnetischer Träger und medizinisches Präparat zur kontrollierbaren Zuführung und Freisetzung von Wirkstoffen, Herstellungsverfahren dafür und Behandlungsverfahren unter Verwendung davon |
Also Published As
Publication number | Publication date |
---|---|
AU2010297237A1 (en) | 2012-05-03 |
AU2010297237B2 (en) | 2015-08-20 |
US20110070620A1 (en) | 2011-03-24 |
KR20120070590A (ko) | 2012-06-29 |
JP6037831B2 (ja) | 2016-12-07 |
CN102714080A (zh) | 2012-10-03 |
EP2481061A1 (de) | 2012-08-01 |
BR112012006267A2 (pt) | 2016-05-31 |
RU2554496C9 (ru) | 2016-06-20 |
US8632814B2 (en) | 2014-01-21 |
RU2012115915A (ru) | 2013-10-27 |
JP2013505569A (ja) | 2013-02-14 |
TWI504397B (zh) | 2015-10-21 |
TW201116285A (en) | 2011-05-16 |
US20140093934A1 (en) | 2014-04-03 |
RU2554496C2 (ru) | 2015-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE112006004066B4 (de) | Magnetischer Träger und medizinisches Präparat zur kontrollierbaren Zuführung und Freisetzung von Wirkstoffen, Herstellungsverfahren dafür und Behandlungsverfahren unter Verwendung davon | |
EP1621217B1 (de) | Anitmikrobielles Pulver und Material | |
DE112016003688T5 (de) | Seltenerddauermagnet und Verfahren zur Herstellung desselben | |
EP1644941B1 (de) | Verfahren zur herstellung magnetischer nanopartikel mit verbesserten magneteigenschaften | |
DE68906837T2 (de) | Gesinterte werkstuecke und verfahren zu ihrer herstellung. | |
DE68923695T3 (de) | Gesintertes magnetisches fe-co-material und verfahren zu dessen herstellung. | |
DE102005036858A1 (de) | Verfahren zur Herstellung eines weichmagnetischen Materials | |
WO2009077515A1 (de) | Artikel aus einem formgedächtnis-kompositmaterial, verfahren zu seiner herstellung sowie verfahren zum abrufen gespeicherter formen | |
DE102005035434A1 (de) | Zellkulturträger, Verfahren zum Herstellen von Zellkulturträgern und Verfahren zur Zellkultivierung | |
WO2011033084A1 (de) | Schaltbare ferromagnetische nanoteilchen enthaltende substrate | |
DE102015113880A1 (de) | Verfahren zur Herstellung von magnetischen Nd-Fe-B-Materialien mit verringerten schweren Seltenerdmetallen | |
EP2457239A1 (de) | Verwendung diamagnetischer materialien zur bündelung magnetischer feldlinien | |
DE60316748T2 (de) | Magnetischer Träger für biologische Substanzen, Verfahren zur seiner Produktion und seiner Verwendung zur Isolierung dieser biologischen Substanzen | |
AT522913A1 (de) | Verfahren zur Herstellung von Metalloxid- oder Metall-Nanopartikeln | |
DE102004017860A1 (de) | Verfahren und Einrichtung zur Zellkultivierung sowie Zellkulturträger | |
EP2875066B1 (de) | Sphärische, magnetisierbare polyvinylalkohol-mikropartikel, verfahren für deren herstellung, sowie deren verwendung | |
DE112014006035T5 (de) | Verfahren zur Herstellung eines Seltene-Erden-Magneten | |
DE102010039232B4 (de) | Verfahren zur Herstellung von magnetischem Blähglasgranulat | |
DE102007047874B4 (de) | Poröser Formkörper aus Metalloxiden und Verfahren zu seiner Herstellung | |
CH716222B1 (de) | Verfahren zur Herstellung eines R2M17-Magneten. | |
DE69626270T2 (de) | Verfahren zum Herstellen eines druckempfindlichen Materials | |
KR102177475B1 (ko) | 코어-쉘 구조의 무기물-키토산 나노입자 및 이를 포함하는 멤브레인 | |
DE102010020670A1 (de) | Verfahren zur Herstellung eines mehrlagigen metallischen Verbundblechs und Verbundblech | |
EP0099015B1 (de) | Verfahren zur Herstellung von Sinterstahl hoher Raumerfüllung durch Einfachsintertechnik | |
CN117339004A (zh) | 核壳结构的光热响应型多功能离子掺杂复合材料及制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080047135.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10762617 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2012529291 Country of ref document: JP |
|
REEP | Request for entry into the european phase |
Ref document number: 2010762617 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010762617 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010297237 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3450/CHENP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20127010341 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012115915 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2010297237 Country of ref document: AU Date of ref document: 20100917 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012006267 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012006267 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120320 |